Coronary Artery Disease
Platelet glycoprotein IIb/IIIa receptor inhibitors: Is their future as bright as their past?
Massoud A. Leesar MD, FSCAI, FACC,
Corresponding Author
Massoud A. Leesar MD, FSCAI, FACC
Division of Cardiology Cardiac and Vascular Invasive Services, University of Cincinnati College of Medicine Cincinnati, Ohio
Division of Cardiology, Director, Cardiac and Vascular Invasive Services, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0542
Search for more papers by this author
Massoud A. Leesar MD, FSCAI, FACC,
Corresponding Author
Massoud A. Leesar MD, FSCAI, FACC
Division of Cardiology Cardiac and Vascular Invasive Services, University of Cincinnati College of Medicine Cincinnati, Ohio
Division of Cardiology, Director, Cardiac and Vascular Invasive Services, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0542
Search for more papers by this author
First published: 22 May 2008
No abstract is available for this article.
REFERENCES
- 1
EPISTENT investigators.
Randomized placebo-controlled and balloon angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockage.
Lancet
1998;
352:
87–92.
- 2
Kastrati A,Mehilli J,Schuhlen H, et al., For the intracoronary stenting and antithrombotic regimen-rapid early action for coronary treatment (ISAR-REACT) study investigators.
A clinical trial of abciximab in elective percutaneous intervention after pretreatment with clopidogrel.
N Engl J Med
2004;
350:
232–238.
- 3
Mehilli J,Kastrati A,Schuhlen H, et al.
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary intervention after treatment with a high loading dose of clopidogrel.
Circulation
2004;
110:
3627–3635.
- 4
Kirtane AJ,Ellis SG,Dawkins KD, et al.
Paclitaxel-eluting coronary stents in patients with diabetes mellitus.
J Am Coll Cardiol
2008;
51:
708–715.
- 5
Nikolsky E,Holmes DR,Mehran R, et al.
Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.
Cathet Cardiovasc Interv, in press.
